Practical Usability of EGFR Mutation Detection in ctDNA From Resectable NSCLC

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04922073

Enrollment

150

Registered

2021-06-10

Start date

2021-06-01

Completion date

2022-03-31

Last updated

2021-08-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung Neoplasms

Brief summary

The aim of the study is to assess the practical usability of EGFR mutation detection in ctDNA from early NSCLC.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

20 Years to 85 Years

Inclusion criteria

* Patient with clinical stage IB to IIIA Non-small Cell Lung Cancer * Patients with resectable lung cancer * One of followings: 1) Never-smokers or ex-smokers who quit 10 years ago, 2) Female 3) Subsolid nodule in chest CT 4) Biopsy-proven adenocarcinoma

Exclusion criteria

* Patients with metastatic lung cancer (Stage IIIB-IV) * Patients who underwent chemotherapy or radiotherapy * Patients with other malignancies

Design outcomes

Primary

Measure	Time frame	Description
Performance of the EGFR assay	Immediately before the surgery	ADPS EGFR Mutation Test using plasma sample from clinical stage IB-IIIA NSCLC patients (reference: EGFR assay in tissue specimen)

Countries

South Korea

Contacts

Primary ContactJhingook Kim, MD

jhingookkim@gmail.com82-2-3410-1696

Outcome results